Weekly Semaglutide Shows Promise for Blood Sugar and Weight Management in Adults with Type 1 Diabetes

A recent clinical trial has demonstrated that weekly administration of semaglutide, a medication traditionally used for type 2 diabetes and obesity, may offer significant benefits for adults with type 1 diabetes who use automated insulin delivery systems. The 26-week double-blind study, involving 72 participants across multiple medical centers including Oregon Health & Science University, revealed that those treated with semaglutide experienced notable improvements in blood sugar control and weight loss. Specifically, 36% of patients on the drug achieved all three primary health goals: improved blood glucose levels, reduced time in hypoglycemia, and a weight reduction of at least 5%, compared to no patients in the placebo group. On average, participants lost approximately 18.5 pounds over six months and showed modest improvements in their A1C levels, all without an increased risk of hypoglycemia or serious complications like diabetic ketoacidosis. These findings are published in NEJM Evidence and mark a significant step toward expanding the potential uses of semaglutide beyond its current indications. While still investigational for type 1 diabetes, this study provides promising evidence for its effectiveness in patients already using automated insulin systems. Dr. Viral Shah from Indiana University and Dr. Andrew Ahmann from Oregon Health & Science University led the research team. The study’s success opens new avenues for managing type 1 diabetes, focusing on comprehensive blood sugar and weight regulation, which are critical components of overall health in diabetic patients.